Bioeconomy key to future, says OECD report

8 June 2009

Biotechnology has the power to improve human health, address environmental challenges and change the way the world does business,  according to a new Organization for Economic Cooperation and Development  report, The Bioeconomy to 2030: Designing a Policy Agenda, examines the  role of biotechnology in the global economy over the next two decades  and outlines policies that could maximize its benefits.

Already biotech-based drugs provide greater health advantages than their  traditional counterparts. By 2015 virtually all new drugs, about half of  global production of the world's major crops and an increasing number of  everyday products (eg, food additives, plastics, fuels and detergents)  will be produced using biotechnology. New crop varieties under  development could increase global food production while requiring less  water, pesticides and fertilizers.

Biotech could produce 2.7% of GDP by 2030

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight